drugset / Trial / NCT02900469

Presurgical Trial of Denosumab in Breast Cancer

NCT02900469

Phase 0 Completed 44 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether one dose of denosumab can lead to changes in the tumor, which may decrease the ability of tumor to spread.

Timeline

Start
2016-10
Primary completion
2019-12-03
Completion
2020-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 120 mg Subcutaneous

Indications